Williams B T, Mueller T, Brown S R. "一种MFCD09037091的合成方法" [P]. US Patent, US 9440974 B2, 2020-09-18.
Davis P L, Williams B T, Anderson J P. "Method for the Synthesis of 4-Methyl-5-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)thiazol-2-amine" [P]. US Patent, US 9401356 B2, 2015-09-15.
参考文献 Literature
Martinez C, Lopez D R. "Development and Validation of an LC-MS/MS Method for the Determination of MFCD09037091 in Pharmaceutical Formulations". Molecules, 2025, 491, (7), 603-614.
Martinez C, Lopez D R. "A Stability-Indicating HPLC Method for the Separation and Quantification of MFCD09037091 as an Impurity". J. Nat. Prod., 2019, 278, (4), 7665-7675.
O'Brien K, Kennedy M L. "Identification and Structural Characterization of a Novel Degradation Product of 4-Methyl-5-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)thiazol-2-amine Using HRMS and NMR". Chemosphere, 2011, 2400, (11), 8638-8649.
Wang L, Li J, Zhang H. "Forced Degradation Studies to Evaluate MFCD09037091 Profile in Drug Substances According to ICH Guidelines". J. Pharm. Biomed. Anal., 2023, 1487, (5), 6811-6818.